V
19.31
-0.36 (-1.83%)
| Penutupan Terdahulu | 19.67 |
| Buka | 19.44 |
| Jumlah Dagangan | 466,127 |
| Purata Dagangan (3B) | 1,267,104 |
| Modal Pasaran | 1,529,597,312 |
| Harga / Jualan (P/S) | 3.93 |
| Harga / Buku (P/B) | 3.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -97,069.76% |
| EPS Cair (TTM) | -4.32 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.29% |
| Nisbah Semasa (MRQ) | 18.55 |
| Aliran Tunai Operasi (OCF TTM) | -196.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -104.01 M |
| Pulangan Atas Aset (ROA TTM) | -32.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Viridian Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | 1.00 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.01% |
| % Dimiliki oleh Institusi | 112.35% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 47.00 (RBC Capital, 143.40%) | Beli |
| Median | 36.00 (86.43%) | |
| Rendah | 27.00 (Wells Fargo, 39.82%) | Pegang |
| Purata | 36.50 (89.02%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 20.35 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 19 Dec 2024 | 27.00 (39.82%) | Pegang | 18.73 |
| HC Wainwright & Co. | 17 Dec 2024 | 34.00 (76.07%) | Beli | 20.82 |
| 16 Dec 2024 | 34.00 (76.07%) | Beli | 21.54 | |
| RBC Capital | 17 Dec 2024 | 47.00 (143.40%) | Beli | 20.82 |
| 05 Dec 2024 | 44.00 (127.86%) | Beli | 19.63 | |
| Needham | 25 Nov 2024 | 38.00 (96.79%) | Beli | 21.03 |
| 13 Nov 2024 | 38.00 (96.79%) | Beli | 22.48 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Dec 2024 | Pengumuman | Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease |
| 13 Dec 2024 | Pengumuman | Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 |
| 04 Dec 2024 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Nov 2024 | Pengumuman | Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data |
| 05 Nov 2024 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |